Cost of poor blood pressure control in the UK: 62,000 unnecessary deaths per year
- PMID: 12821951
- DOI: 10.1038/sj.jhh.1001581
Cost of poor blood pressure control in the UK: 62,000 unnecessary deaths per year
Abstract
High blood pressure is the most important risk factor for cardiovascular disease. With the information on systolic blood pressure from the recently published meta-analysis of prospective studies, we calculated the reductions in stroke and ischaemic heart disease with control of all hypertensives to a systolic blood pressure of 140 mmHg. For adults there would be a reduction of 28-44% in stroke and 20-35% in ischaemic heart disease depending on age. In the UK, this would prevent approximately 21,400 stroke deaths and 41,400 ischaemic heart disease deaths each year. Around half of those who suffer a stroke or ischaemic heart disease survive, there would be a proportionate decrease in these people as well. These amount to approximately 42,800 strokes and 82,800 ischaemic heart diseases saved, making a total of 125,600 events saved a year in the UK. This would result in a reduction in disability and major cost savings both to individuals, their families and the Health Service. The blood pressure levels and control of blood pressure in many countries are similar to those in the UK, so the reductions in stroke and ischaemic heart disease worldwide, if the same control of high blood pressure could be obtained, would be immense.
Similar articles
-
The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke.J Med Screen. 2004;11(1):3-7. doi: 10.1177/096914130301100102. J Med Screen. 2004. PMID: 15006106
-
Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.Public Health. 2006 Dec;120(12):1140-8. doi: 10.1016/j.puhe.2006.10.012. Epub 2006 Nov 3. Public Health. 2006. PMID: 17084425
-
Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment.Lancet. 2006 Nov 11;368(9548):1651-9. doi: 10.1016/S0140-6736(06)69700-6. Lancet. 2006. PMID: 17098083 Review.
-
Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).Pharmacotherapy. 2012 Jun;32(6):527-37. doi: 10.1002/j.1875-9114.2012.01097.x. Epub 2012 May 2. Pharmacotherapy. 2012. PMID: 22552863 Clinical Trial.
-
Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation.Arch Iran Med. 2012 Sep;15(9):531-7. Arch Iran Med. 2012. PMID: 22924369 Review.
Cited by
-
Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring.Drugs R D. 2014 Jun;14(2):31-43. doi: 10.1007/s40268-014-0049-5. Drugs R D. 2014. PMID: 24842751 Free PMC article. Review.
-
Physical health indicators in major mental illness: analysis of QOF data across UK general practice.Br J Gen Pract. 2014 Oct;64(627):e649-56. doi: 10.3399/bjgp14X681829. Br J Gen Pract. 2014. PMID: 25267051 Free PMC article.
-
Therapeutic RNA-silencing oligonucleotides in metabolic diseases.Nat Rev Drug Discov. 2022 Jun;21(6):417-439. doi: 10.1038/s41573-022-00407-5. Epub 2022 Feb 24. Nat Rev Drug Discov. 2022. PMID: 35210608 Review.
-
A Novel Ultrasensitive Second Derivative Synchronous Spectrofluorimetric Approach for the Simultaneous Analysis of the Co-Administered Antihypertensives, Telmisartan and Carvedilol in Biological Fluids and Tablets: Greenness and Blueness Assessment.J Fluoresc. 2024 Dec 14. doi: 10.1007/s10895-024-04064-2. Online ahead of print. J Fluoresc. 2024. PMID: 39673662
-
Under pressure.Br J Gen Pract. 2006 Aug;56(529):627. Br J Gen Pract. 2006. PMID: 16882384 Free PMC article. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical